BA
SRPT icon

Boston Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Boston Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$1.61M Buy
21,350
+9,329
+78% +$1.1M 0.08% 291
2019
Q2 		$1.83M Buy
12,021
+766
+7% +$93.1K 0.1% 237
2019
Q1 		$1.34M Buy
11,255
+3,405
+43% +$438K 0.07% 293
2018
Q4 		$857K Sell
7,850
-1,705
-18% -$213K 0.05% 346
2018
Q3 		$1.54M Buy
9,555
+226
+2% +$30.9K 0.07% 312
2018
Q2 		$1.23M Sell
9,329
-17,149
-65% -$1.62M 0.03% 337
2018
Q1 		$1.96M Buy
+26,478
New +$1.77M 0.05% 280

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Boston Advisors's SRPT Position: Q3 2019 in Review

Boston Advisors increased its Sarepta Therapeutics (SRPT) stake by 78% in Q3 2019, buying an estimated $1.1M and bringing the position to 21,350 shares worth $1.61M. The position accounts for 0.08% of the portfolio, ranked #291.

Boston Advisors first reported a position in SRPT in Q1 2018 and has held it in 7 quarters since. The position peaked at $1.96M in Q1 2018. 340 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

  • Boston Advisors held 21,350 shares of Sarepta Therapeutics worth $1.61M as of Q3 2019.
  • Boston Advisors bought 9,329 Sarepta Therapeutics shares in Q3 2019, an estimated $1.1M.
  • Sarepta Therapeutics made up 0.08% of Boston Advisors's portfolio in Q3 2019, its #291 holding.
  • Boston Advisors first reported a position in Sarepta Therapeutics in Q1 2018 and has held it in 7 quarters since.
  • Boston Advisors's Sarepta Therapeutics position peaked at $1.96M in Q1 2018.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on Boston Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.